277 related articles for article (PubMed ID: 25300810)
21. Acquired von Willebrand Syndrome During the Course of Myelofibrosis: Analysis of 32 Cases.
Mital A; Prejzner W; Hellmann A
Adv Clin Exp Med; 2015; 24(6):1001-6. PubMed ID: 26771972
[TBL] [Abstract][Full Text] [Related]
22. Laboratory Testing for von Willebrand Factor Antigen (VWF:Ag).
Favaloro EJ; Mohammed S; Patzke J
Methods Mol Biol; 2017; 1646():403-416. PubMed ID: 28804844
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome.
Stufano F; Boscarino M; Bucciarelli P; Baronciani L; Maino A; Cozzi G; Peyvandi F
Semin Thromb Hemost; 2019 Feb; 45(1):36-42. PubMed ID: 29913537
[TBL] [Abstract][Full Text] [Related]
24. Acquired von Willebrand syndrome in adult patients with congenital heart disease.
Waldow HC; Westhoff-Bleck M; Widera C; Templin C; von Depka M
Int J Cardiol; 2014 Oct; 176(3):739-45. PubMed ID: 25139318
[TBL] [Abstract][Full Text] [Related]
25. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update.
Federici AB; Budde U; Castaman G; Rand JH; Tiede A
Semin Thromb Hemost; 2013 Mar; 39(2):191-201. PubMed ID: 23397553
[TBL] [Abstract][Full Text] [Related]
26. Laboratory Testing for von Willebrand Factor Collagen Binding (VWF:CB).
Favaloro EJ; Mohammed S
Methods Mol Biol; 2017; 1646():417-433. PubMed ID: 28804845
[TBL] [Abstract][Full Text] [Related]
27. Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome.
van Genderen PJ; Boertjes RC; van Mourik JA
Thromb Haemost; 1998 Sep; 80(3):495-8. PubMed ID: 9759633
[TBL] [Abstract][Full Text] [Related]
28. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders.
Federici AB
Semin Hematol; 2006 Jan; 43(1 Suppl 1):S48-58. PubMed ID: 16427386
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome.
Karger R; Weippert-Kretschmer M; Budde U; Kretschmer V
Blood Coagul Fibrinolysis; 2011 Mar; 22(2):144-7. PubMed ID: 21178586
[TBL] [Abstract][Full Text] [Related]
30. Autoantibody to von Willebrand factor in systemic lupus erythematosus.
Soff GA; Green D
J Lab Clin Med; 1993 Mar; 121(3):424-30. PubMed ID: 8445290
[TBL] [Abstract][Full Text] [Related]
31. Acquired von Willebrand syndrome (AvWS).
Drenko P; Přenosilová P; Lavičková A
Vnitr Lek; 2022; 68(E-4):16-19. PubMed ID: 36220373
[TBL] [Abstract][Full Text] [Related]
32. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease.
Caron C; Hilbert L; Vanhoorelbeke K; Deckmyn H; Goudemand J; Mazurier C
Br J Haematol; 2006 Jun; 133(6):655-63. PubMed ID: 16704443
[TBL] [Abstract][Full Text] [Related]
33. Early diagnosis of acquired von Willebrand Syndrome (AVWS) is elementary for clinical practice in patients treated with ECMO therapy.
Kalbhenn J; Schmidt R; Nakamura L; Schelling J; Rosenfelder S; Zieger B
J Atheroscler Thromb; 2015; 22(3):265-71. PubMed ID: 25186021
[TBL] [Abstract][Full Text] [Related]
34. Acquired von Willebrand syndrome: data from an international registry.
Federici AB; Rand JH; Bucciarelli P; Budde U; van Genderen PJ; Mohri H; Meyer D; Rodeghiero F; Sadler JE;
Thromb Haemost; 2000 Aug; 84(2):345-9. PubMed ID: 10959711
[TBL] [Abstract][Full Text] [Related]
35. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
Turecek PL; Siekmann J; Schwarz HP
Semin Thromb Hemost; 2002 Apr; 28(2):149-60. PubMed ID: 11992238
[TBL] [Abstract][Full Text] [Related]
36. Causes, etiology and diagnosis of acquired von Willebrand disease: a prospective diagnostic workup to establish the most effective therapeutic strategies.
Sucker C; Michiels JJ; Zotz RB
Acta Haematol; 2009; 121(2-3):177-82. PubMed ID: 19506364
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy.
Lavin M; Brophy TM; Rawley O; O'Sullivan JM; Hayden PJ; Browne PV; Ryan K; O'Connell N; O'Donnell JS
J Thromb Haemost; 2016 Jun; 14(6):1200-5. PubMed ID: 26991062
[TBL] [Abstract][Full Text] [Related]
38. Acquired von Willebrand syndrome: features and management.
Mohri H
Am J Hematol; 2006 Aug; 81(8):616-23. PubMed ID: 16823821
[TBL] [Abstract][Full Text] [Related]
39. Acquired von Willebrand syndrome: an update.
Franchini M; Lippi G
Am J Hematol; 2007 May; 82(5):368-75. PubMed ID: 17133419
[TBL] [Abstract][Full Text] [Related]
40. Acquired von Willebrand syndrome in patients with ventricular assist device or total artificial heart.
Heilmann C; Geisen U; Beyersdorf F; Nakamura L; Benk C; Berchtold-Herz M; Trummer G; Schlensak C; Zieger B
Thromb Haemost; 2010 May; 103(5):962-7. PubMed ID: 20352153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
